Nurix Therapeutics, Inc. · Brief

Next report

87 days

Jan 27 · after closeest.Q4 FY26

Expected move

No implied move.

8 reportsHistory

0 of 8≥ implied

Jan 28 '25±12.1%▲+0.46%×0.04

Apr 8 '25±33.4%▲+3.67%×0.11

Jul 9 '25±13.5%▼−3.87%×0.29

Oct 9 '25±17.0%▼−10.13%×0.60

Q1 FY26±17.3%▼−1.57%×0.09

Apr 8 '26±25.7%▼−4.59%×0.18

Q2 FY26±16.5%▼−6.60%×0.40

Q3 FY26±17.9%▼−0.14%×0.01

quarterimplied−35%0+35%realized×

Q3 FY26±17.9%▼−0.14%×0.01

Q2 FY26±16.5%▼−6.60%×0.40

Apr '26±25.7%▼−4.59%×0.18

Q1 FY26±17.3%▼−1.57%×0.09

Oct '25±17.0%▼−10.13%×0.60

Jul '25±13.5%▼−3.87%×0.29

2 older reports

Apr '25±33.4%▲+3.67%×0.11

Jan '25±12.1%▲+0.46%×0.04

Shaded = implied · tick ▲▼ = realized · × = |realized| ÷ impliedSource: options EOD · implied at prior close · realized close to close

Jan 27 report · est.

Bull2

7disclosed supplier and customer ties in SEC filingsSEC filings

212managers reporting a position in the latest quarterly filings13F · Jun 30 '26

Bear2 of 3

4tracked funds holding the companyN-PORT · Aug 31 '26

0.56%of State Street SPDR S&P Biotech ETF's assets, largest tracked fund weightN-PORT · Jun 30 '26

AI captions · Oct 19 '26once per report · top 2 per case

NRIX report session

No linked exposure.

Oct 12impliedImplied move: ±17.9% into Oct 13 earnings (Oct 12 close).Source

Oct 8impliedImplied move: ±7.9% into Oct 12 earnings (Oct 8 close).Source

privateThesis 0 · Decisions 0 · Observations 0

No thesis.